^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

Published date:
09/30/2023
Excerpt:
Vobra duo treatment for 4 weeks further increased survival in both orthotopic and resected NB models….Vobra duo exerts relevant antitumor activity in preclinical B7-H3-expressing NB models…
DOI:
10.1136/jitc-2023-007174